Protective effect of bromocriptine against BH4-induced Cath.a cell death involving up-regulation of antioxidant enzymes.
Ju Hee Lim, Sa Suk Kim, Doo Hyun Boo...
https://pubmed.ncbi.nlm.nih.gov/19146917/Actively Recruiting
Led by Jimma University · Updated on 2024-11-19
112
Participants Needed
1
Research Sites
26 weeks
Total Duration
Dilated cardiomyopathy DCM is a heart condition that causes enlargement and weakening of the hearts ventricles, leading to heart failure, especially in younger adults. This research evaluates the potential benefits of the drug bromocriptine in women of reproductive age with DCM. Bromocriptine has shown promise in treating a related condition called peripartum cardiomyopathy PPCM by reducing harmful hormone levels, and this study aims to see if it can help a broader group of women with DCM. The trial compares two groups of women with DCM one group receives bromocriptine 2.5 mg orally every day for 8 weeks along with standard heart failure treatment, and the other group receives placebo pills plus standard treatment. The study is randomized and open-label, meaning participants are assigned by chance to either group, and both groups receive guideline-directed medical therapy. Bromocriptines effects on heart function and safety will be closely monitored during the treatment period. Participants will be followed for up to 12 months, with assessments at 3, 6, 9, and 12 months. These include tests of heart function, blood markers related to heart failure, clinical evaluations, and quality of life measures. Researchers will also track hospitalizations and functional improvements. The study will measure bromocriptine blood levels to understand how the drug behaves in this population, aiming to provide detailed information about its potential benefits and safety.
CONDITIONS
Bromocriptine in Dilated Cardiomyopathy Among Women of Reproductive Age
K
Kedir N Tukeni, MD
E
Esayas K Gudina, MD,PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Jimma University
Lead Sponsor
Ludwig-Maximilians - University of Munich
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 8 weeks
Participants receive either bromocriptine 2.5 mg daily for 8 weeks plus standard heart failure therapy or placebo plus standard therapy.
Weekly visits for up to 8 weeks
Duration - Up to 12 months
Participants are monitored for cardiac function, clinical improvement, hospitalization, and quality of life after treatment ends.
Visits at 3, 6, 9, and 12 months
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Ju Hee Lim, Sa Suk Kim, Doo Hyun Boo...
https://pubmed.ncbi.nlm.nih.gov/19146917/Prabhakaran Gopalakrishnan, Robert Biederman
https://pubmed.ncbi.nlm.nih.gov/32298005/Stacey Peters, Renee Johnson, Samuel Birch...
https://pubmed.ncbi.nlm.nih.gov/31974027/Angkawipa Trongtorsak, Veraprapas Kittipibul, Sunita Mahabir...
https://pubmed.ncbi.nlm.nih.gov/34725781/Ian S Patten, Sarosh Rana, Sajid Shahul...
https://pubmed.ncbi.nlm.nih.gov/22596155/D Reichart, C Magnussen, T Zeller...
https://pubmed.ncbi.nlm.nih.gov/31132311/Karen Sliwa, Lori Blauwet, Kemi Tibazarwa...
https://pubmed.ncbi.nlm.nih.gov/20308616/Julie Halkein, Sebastien P Tabruyn, Melanie Ricke-Hoch...
https://pubmed.ncbi.nlm.nih.gov/23619365/Morteza Samini, Leila Moezi, Naghmeh Jabarizadeh...
https://pubmed.ncbi.nlm.nih.gov/12457625/Awoke Misganaw, Damen Haile Mariam, Ahmed Ali...
https://pubmed.ncbi.nlm.nih.gov/24847587/Jimma University
Lead Sponsor
Ludwig-Maximilians - University of Munich
Collaborating Sponsor